What type of study is this?

Eligibility for icosapent ethyl 1–3 months after acute coronary syndrome and the risk for myocardial re-infarction: Data from the CALLINICUS-Hellas Registry

View Full Paper

Ask AI

Bookmark

Patients eligible for icosapent ethyl showed a higher risk of non-fatal myocardial reinfarction within 12 months.
Approximately 25.6% of post-ACS patients met the criteria for receiving icosapent ethyl, with diabetes showing a higher eligibility of 32.6%.
The CALLINICUS-Hellas registry assessed 1254 ACS patients, evaluating their lipid profiles and corresponding CV events.
Findings highlight that early Icosapent ethyl administration could help reduce the residual cardiovascular risk associated with high triglycerides.

No takes yet. Share an insight, caveat, or question.

Observational analysis found icosapent ethyl eligibility impacts cardiovascular outcomes in ACS patients, indicating a need for timely intervention.

Rallidis et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis found icosapent ethyl eligibility impacts cardiovascular outcomes in ACS patients, indicating a need for timely intervention.